Crossmark

Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study

Crossref DOI link: https://doi.org/10.1186/s12883-021-02347-w

Published Online: 2021-08-23

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Patti, Francesco

Penaherrera, Javier Nicolas

Zieger, Lorissa

Wicklein, Eva-Maria
License Information

Text and Data Mining valid from 2021-08-23

Version of Record valid from 2021-08-23
More Information

Article History

Received: 1 March 2021

Accepted: 28 July 2021

First Online: 23 August 2021

Declarations

:

: This was a <i>post-hoc</i> analysis of a 2-year, prospective, international, observational study, and all data collected were anonymised to preserve participant anonymity and confidentiality. Approval from ethics committee was obtained (CT 1, Azienda Ospedaliero Universitaria Policlinico Vittori Emanuele Catania Comitato Etica, Via Santa), and sites were requested to obtain written informed consent from each patient prior to inclusion into the study.

: Not applicable

: FP has received personal compensation for speaking activities and serving on an advisory board by Almirall, Bayer, Biogen, Celgene, Merck, Novartis, Roche, Sanofi Genzyme, and TEVA. He also received research grants by Biogen, Merck, FISM (Fondazione Italiana Sclerosi Multipla), RELOAD Onlus Association, and University of Catania.JP is an employee at Bayer AG.LZ was an employee of Parexel at the time of this analysis.EW is an employee at Bayer AG.

Document is current

Any future updates will be listed below